BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 26933805)

  • 1. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
    Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
    Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
    Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
    Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
    Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
    Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
    Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
    Crippa E; Folini M; Pennati M; Zaffaroni N; Pierotti MA; Gariboldi M
    Oncotarget; 2016 Apr; 7(14):18594-604. PubMed ID: 26919240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
    Abdel-Sater F; Najar M; Fayyad-Kazan H
    J Cell Physiol; 2020 Jun; 235(6):5204-5212. PubMed ID: 31736084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
    PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
    Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
    Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of microRNAs in triple-negative breast cancer.
    Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
    Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA in breast cancer: The association with BRCA1/2.
    Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
    Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
    Song W; Tang L; Xu Y; Xu J; Zhang W; Xie H; Wang S; Guan X
    Sci Rep; 2017 Feb; 7():42319. PubMed ID: 28176879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
    Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.
    Gao S; Wang Y; Wang M; Li Z; Zhao Z; Wang RX; Wu R; Yuan Z; Cui R; Jiao K; Wang L; Ouyang L; Liu R
    Oncotarget; 2017 Jun; 8(25):41451-41464. PubMed ID: 28562349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
    Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
    Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.